Janus Henderson Group PLC Grows Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Janus Henderson Group PLC boosted its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 8.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 7,379,309 shares of the company's stock after acquiring an additional 566,146 shares during the period. Janus Henderson Group PLC owned 7.25% of Dyne Therapeutics worth $173,808,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Geode Capital Management LLC grew its holdings in Dyne Therapeutics by 1.5% in the 4th quarter. Geode Capital Management LLC now owns 1,887,329 shares of the company's stock worth $44,476,000 after acquiring an additional 27,916 shares during the last quarter. Jefferies Financial Group Inc. bought a new stake in Dyne Therapeutics in the 4th quarter worth $42,408,000. Norges Bank bought a new stake in Dyne Therapeutics in the 4th quarter worth $22,384,000. ArrowMark Colorado Holdings LLC boosted its stake in shares of Dyne Therapeutics by 3.6% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 932,231 shares of the company's stock valued at $21,963,000 after purchasing an additional 32,041 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Dyne Therapeutics by 7.7% during the 4th quarter. Northern Trust Corp now owns 777,013 shares of the company's stock valued at $18,306,000 after purchasing an additional 55,511 shares in the last quarter. Institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Price Performance

NASDAQ:DYN traded up $0.09 during mid-day trading on Friday, hitting $11.83. 2,185,589 shares of the company's stock were exchanged, compared to its average volume of 1,679,246. Dyne Therapeutics, Inc. has a one year low of $6.36 and a one year high of $47.45. The business has a fifty day moving average price of $10.36 and a 200 day moving average price of $17.43. The company has a market cap of $1.34 billion, a PE ratio of -3.32 and a beta of 1.19.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, equities analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on DYN. Piper Sandler cut their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. BMO Capital Markets began coverage on shares of Dyne Therapeutics in a research note on Wednesday, March 12th. They set an "outperform" rating and a $50.00 target price on the stock. Guggenheim reaffirmed a "buy" rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. HC Wainwright cut their target price on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Finally, JPMorgan Chase & Co. cut their target price on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $46.85.

Insiders Place Their Bets

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the transaction, the insider now directly owns 199,087 shares of the company's stock, valued at approximately $2,777,263.65. The trade was a 1.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders sold 6,237 shares of company stock valued at $77,760. Insiders own 14.14% of the company's stock.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.